# NVO — slm-full-cpu

## Metadata

ticker: NVO
arm: slm-full-cpu
judge_prompt_version: v2
context_sha256: 3656dfd282730af0c11e959b8cef2222b7495f024e3153a2164eca085ecec7db
slm_endpoint: slm-cpu
slm_url: http://llamacpp.financial-agent.svc:8080
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 5
llm_endpoints: slm-cpu
llm_by_site: {"section:financial_health": {"calls": 1, "completion_tokens": 138, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 29.826, "latency_s_total": 29.826, "parse_failure": 0, "prompt_tokens": 311, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 147, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 30.892, "latency_s_total": 30.892, "parse_failure": 0, "prompt_tokens": 305, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 141, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 37.948, "latency_s_total": 37.948, "parse_failure": 0, "prompt_tokens": 301, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 74, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 18.144, "latency_s_total": 18.144, "parse_failure": 0, "prompt_tokens": 309, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 796, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 85.473, "latency_s_total": 85.473, "parse_failure": 0, "prompt_tokens": 1378, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "NVO",
  "company_name": "Novo Nordisk A/S",
  "current_price": 37.32,
  "currency": "USD",
  "market_cap": 164789452800.0,
  "pe_ratio": 9.400503,
  "forward_pe": 11.231421,
  "week_52_high": 64.16,
  "week_52_low": 35.12,
  "revenue": 329430990848.0,
  "net_income": 116442996736.0,
  "profit_margin": 0.35347,
  "dividend_yield": 4.81,
  "sector": "Healthcare",
  "industry": "Drug Manufacturers - General"
}

NEWS ARTICLES:
[]

SEC FILING SUMMARIES:
{
  "10-K": {
    "message": "No 10-K found"
  },
  "10-Q": {
    "message": "No 10-Q found"
  }
}

RAG — SEC HIGHLIGHTS:
(not available)

RAG — RISK FACTORS:
(not available)

## Pre-written sections (judge input)

### Financial Health

Novo Nordisk A/S (NVO) currently trades at $37.32 with a substantial market capitalization of approximately $164.8 billion. The company demonstrates robust profitability, reporting a net income of $116.4 billion on revenues of $329.4 billion, resulting in an impressive profit margin of 35.35%. Its trailing P/E ratio stands at a relatively compressed 9.40, suggesting potential undervaluation relative to its earnings power. This strong financial foundation is further supported by a healthy dividend yield of 4.81%, indicating consistent cash flow generation and shareholder returns.

### Recent Developments

As no recent news filings or press releases are currently available, the investment focus remains on the company's strong underlying fundamentals, including a robust 35.3% profit margin and a 4.81% dividend yield. The stock is currently trading near its 52-week low of $35.12, presenting a potential entry point for investors seeking value relative to its $164.8 billion market capitalization. With a forward P/E of 11.23, the valuation appears attractive compared to historical averages, suggesting market optimism for future growth in its diabetes and obesity treatment portfolios. Investors should monitor upcoming quarterly reports for updates on demand trends and supply chain capacity.

### SEC Filing Highlights
No recent 10-K or 10-Q filings were available for Novo Nordisk A/S (NVO) in the provided dataset. Consequently, specific operational updates or financial metrics from the most recent quarterly or annual report cannot be extracted. Investors are advised to consult the official SEC EDGAR database directly for the latest regulatory disclosures.

### Risk Factors

*   **Regulatory and Pricing Pressure:** Potential for government-mandated price controls or reimbursement restrictions on GLP-1 agonists (e.g., Ozempic, Wegovy) in key markets like the US and EU, which could compress profit margins.
*   **Supply Chain and Manufacturing Constraints:** Inability to scale production capacity quickly enough to meet surging global demand, leading to supply shortages that may result in lost sales and reputational damage.
*   **Competitive Landscape and Patent Cliffs:** Increasing competition from rival pharmaceutical companies developing next-generation weight-loss and diabetes drugs, alongside the eventual expiration of key patents protecting Novo Nordisk’s core revenue streams.

## Audited (Exec Summary + Outlook)

### Executive Summary
Novo Nordisk A/S is a dominant leader in the diabetes and obesity treatment markets, currently demonstrating robust profitability with a 35.35% net income margin on $329.4 billion in revenues. The stock is notable now as it trades near its 52-week low of $35.12, offering a potential value entry point with a compressed trailing P/E of 9.40 and a healthy 4.81% dividend yield. The single most important near-term variable shaping the outcome is the company's ability to scale manufacturing capacity to meet surging global demand without triggering regulatory pricing pressures or competitive erosion.

### Outlook
The directional outlook for Novo Nordisk remains cautiously constructive, driven by the structural tailwinds of expanding demand for GLP-1 therapies, though this is counterbalanced by significant headwinds regarding manufacturing scalability and potential regulatory pricing interventions. Investors should closely monitor the trajectory of supply chain execution and any shifts in reimbursement policies in key markets, as these variables will determine whether the company can sustain its current margin profile. The thesis would be strengthened by evidence of successful capacity expansion and sustained pricing power, whereas a weakening view would result from visible supply bottlenecks leading to lost sales or aggressive competitive entry eroding market share.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now audit every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number appearing in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "35.35% net income margin"
LABEL: SUPPORTED
REASON: The source data lists `profit_margin: 0.35347`, which equals 35.347%, rounding to 35.35% — within 0.15 percentage points of the stated figure.

---

CLAIM: "$329.4 billion in revenues"
LABEL: SUPPORTED
REASON: The source data lists `revenue: 329430990848.0`, which equals approximately $329.4 billion.

---

CLAIM: "trades near its 52-week low of $35.12"
LABEL: SUPPORTED
REASON: The source data confirms `week_52_low: 35.12` and `current_price: 37.32`; at $37.32 the stock is $2.20 above its 52-week low, which is consistent with "near its 52-week low" — arithmetically verified (37.32 is ~5.9% above 35.12, well within a reasonable interpretation of "near").

---

CLAIM: "trailing P/E of 9.40"
LABEL: SUPPORTED
REASON: The source data lists `pe_ratio: 9.400503`, which rounds directly to 9.40.

---

CLAIM: "4.81% dividend yield"
LABEL: SUPPORTED
REASON: The source data lists `dividend_yield: 4.81`, matching exactly.

---

**OUTLOOK**

The Outlook section contains no specific quantitative figures, price targets, thresholds, ratios, metrics, percentages, named product milestones, or forward-looking numbers. All statements are qualitative and directional in nature (e.g., "cautiously constructive," "significant headwinds," "sustained pricing power"). There are therefore no quantitative or forward-looking numerical claims to audit in this section.

---

**SUMMARY TABLE**

| Claim | Label |
|---|---|
| 35.35% net income margin | SUPPORTED |
| $329.4 billion in revenues | SUPPORTED |
| 52-week low of $35.12 | SUPPORTED |
| Trades near its 52-week low | SUPPORTED |
| Trailing P/E of 9.40 | SUPPORTED |
| 4.81% dividend yield | SUPPORTED |

All auditable quantitative claims in the Executive Summary are **SUPPORTED** by the raw source data. The Outlook section contains no quantitative claims requiring audit.
